incabotulinumtoxinA

ApprovedBiologic

MMultiple Sclerosis Center of Northeastern New York

incabotulinumtoxinA is one of 6 biologic programs targeting Lower limb spasticity. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lower Limb SpasticityActive, not recruiting

Lower Limb SpasticityApproved

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Lower Limb Spasticity

#DrugCompanyPhaseTrials

GSK1358820

GSK

Phase 3

1 2

NT 201

MMerz Pharmaceuticals GmbH

Phase 3

—3

incabotulinumtoxinA

MMultiple Sclerosis Center of Northeastern New York

Approved

1 4

Phase 3; MYOBLOC

Supernus Pharmaceuticals, Inc.

Phase 3

1 5

Botox

RRevance Therapeutics, Inc.

Preclinical

9 6

Incobotulinumtoxina 100 UNT

UUniversita di Verona

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lower limb spasticity1 trial

Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients

Completed·MMultiple Sclerosis Center of Northeastern New York·Phase 4·NCT01968902·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for incabotulinumtoxinA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — incabotulinumtoxinA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for incabotulinumtoxinA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Multiple Sclerosis Center of Northeastern New York company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: MMultiple Sclerosis Center of Northeastern New York

incabotulinumtoxinA

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lower limb spasticity1 trial

References

Drug Info

Quick Facts

Related News